Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antidiarrheal rule

This article was originally published in The Tan Sheet

Executive Summary

Relief of travelers' diarrhea is included as an indication for bismuth subsalicylate products in the final monograph for OTC antidiarrheal drug products, effective June 11, FDA reports in the May 12 Federal Register. The condition is described as "a subset of diarrhea occurring in travelers that is most commonly caused by an infectious agent." The approval responds to requests made in response to the 1986 TFM on antidiarrheals (1"The Tan Sheet" April 21, 2003, p. 4). Web materials for Procter & Gamble's Pepto-Bismol already provide information on the condition...

You may also be interested in...



Bismuth Subsalicylate “Relieves Travelers’ Diarrhea” Claim Proposed by FDA

Relief of travelers' diarrhea would be included as an indication for bismuth subsalicylate products in the OTC antidiarrheal drug final monograph under a proposed rule published in the 1April 17 Federal Register

Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty

The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

Topics

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel